摘要
通过介绍法国的临床效益评价,尤其是法国临床效益评价结果对医保准入的影响,进而选取典型案例阐述如何做出具体品种的评价结果和如何据此做出医保准入决定,以期为我国创新药医保目录动态调整提供思路与启示。
It mainly introduced the clinical benefit evaluation of France, and focused on the impact of clinical benefit evaluation results on medical insurance access. On this basis, the typical cases were selected to explain how to make the evaluation results of specific varieties and how to make medical insurance access decisions accordingly so as to provide ideas and enlightenment for the dynamic adjustment of medical insurance catalogue for innovative medicine in China.
作者
赵华婷
颜建周
邵蓉
ZHAO Hua-ting;YAN Jian-zhou;SHAO Rong(The Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University, Nanjing, 211198 , China)
出处
《中国卫生经济》
北大核心
2019年第5期94-96,共3页
Chinese Health Economics
基金
2015年度国家社科基金重大项目(第二批)(15ZDB167)
中国药科大学"双一流"学科创新团队建设项目(CPU2018GY39)
关键词
临床效益评价
医保目录
动态调整
法国
clinical benefit evaluation
medical insurance catalog
dynamic adjustment
France
